Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism

Jeng Fong Chiou, Cheng Jeng Tai, Yu Huei Wang, Tsan Zon Liu, Yee Min Jen, Chia Yang Shiau

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Sorafenib (Nexavar, BAY43-9006), a bi-arylurea, is a newly established anti-cancer drug and its functional attribute of cytotoxicity is based on the multi-kinase inhibitory action. here, we report yet another novel pathway in which sorafenib can induce apoptotic cell death preferentially and efficaciously on an experimentally proven drug- and radio-resistant human hep G2 cells via a mitochondria-dependent oxidative stress mechanism. a real-time confocal imaging assay revealed that sorafenib could rapidly provoke the production of ROS plethorically, mainly concentrating in the mitochondria, albeit substantial amounts of ROS could also be detected in cytosol and nucleus. The rapid production of ROS could simultaneously induce intracellular glutathione (iGSH) depletion. a nearly 90% of iGSH was found to be depleted in 1h period after the cells received the drug treatment. Besides mitochondria, iGSH depletion could also be detected in other cellular compartment including cytoplasm and nucleus. Interestingly, we also demonstrated that sorafenib could trigger mitochondrial Ca2+ overload. all these events compoundedly serve as the final arbitrator to initiate lethal apoptotic process through the release of cytochrome c and caspase 3/7 activation. Collectively, we provide first evidence here that sorafenib can provoke an alternative pathway for apoptosis induction of Hep G2 cells through a mitochondria-dependent oxidative stress mechanism which is independent of original kinase inhibitory attribute of the drug action. Most importantly, we also demonstrate that sorafenib can effectively eradicate a highly drug- and radio-resistant HCC cells. Thus, our data can provide the basis for a potential applicability of sorafenib in a combined treatment modality.

Original languageEnglish
Pages (from-to)1904-1913
Number of pages10
JournalCancer Biology and Therapy
Volume8
Issue number20
DOIs
Publication statusPublished - Oct 15 2009

Fingerprint

Hep G2 Cells
Radio
Mitochondria
Oxidative Stress
Pharmaceutical Preparations
Phosphotransferases
Caspase 7
sorafenib
Caspase 3
Cytosol
Glutathione
Cytoplasm
Cell Death
Apoptosis

Keywords

  • Anti-cancer drug
  • Apoptosis
  • Confocal
  • Hepatocellular carcinoma cell
  • Mitochondria
  • Oxidative stress mechanism
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. / Chiou, Jeng Fong; Tai, Cheng Jeng; Wang, Yu Huei; Liu, Tsan Zon; Jen, Yee Min; Shiau, Chia Yang.

In: Cancer Biology and Therapy, Vol. 8, No. 20, 15.10.2009, p. 1904-1913.

Research output: Contribution to journalArticle

@article{dc37bdec12c64fe0af625d3cc16812b8,
title = "Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism",
abstract = "Sorafenib (Nexavar, BAY43-9006), a bi-arylurea, is a newly established anti-cancer drug and its functional attribute of cytotoxicity is based on the multi-kinase inhibitory action. here, we report yet another novel pathway in which sorafenib can induce apoptotic cell death preferentially and efficaciously on an experimentally proven drug- and radio-resistant human hep G2 cells via a mitochondria-dependent oxidative stress mechanism. a real-time confocal imaging assay revealed that sorafenib could rapidly provoke the production of ROS plethorically, mainly concentrating in the mitochondria, albeit substantial amounts of ROS could also be detected in cytosol and nucleus. The rapid production of ROS could simultaneously induce intracellular glutathione (iGSH) depletion. a nearly 90{\%} of iGSH was found to be depleted in 1h period after the cells received the drug treatment. Besides mitochondria, iGSH depletion could also be detected in other cellular compartment including cytoplasm and nucleus. Interestingly, we also demonstrated that sorafenib could trigger mitochondrial Ca2+ overload. all these events compoundedly serve as the final arbitrator to initiate lethal apoptotic process through the release of cytochrome c and caspase 3/7 activation. Collectively, we provide first evidence here that sorafenib can provoke an alternative pathway for apoptosis induction of Hep G2 cells through a mitochondria-dependent oxidative stress mechanism which is independent of original kinase inhibitory attribute of the drug action. Most importantly, we also demonstrate that sorafenib can effectively eradicate a highly drug- and radio-resistant HCC cells. Thus, our data can provide the basis for a potential applicability of sorafenib in a combined treatment modality.",
keywords = "Anti-cancer drug, Apoptosis, Confocal, Hepatocellular carcinoma cell, Mitochondria, Oxidative stress mechanism, Sorafenib",
author = "Chiou, {Jeng Fong} and Tai, {Cheng Jeng} and Wang, {Yu Huei} and Liu, {Tsan Zon} and Jen, {Yee Min} and Shiau, {Chia Yang}",
year = "2009",
month = "10",
day = "15",
doi = "10.4161/cbt.8.20.9436",
language = "English",
volume = "8",
pages = "1904--1913",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "20",

}

TY - JOUR

T1 - Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism

AU - Chiou, Jeng Fong

AU - Tai, Cheng Jeng

AU - Wang, Yu Huei

AU - Liu, Tsan Zon

AU - Jen, Yee Min

AU - Shiau, Chia Yang

PY - 2009/10/15

Y1 - 2009/10/15

N2 - Sorafenib (Nexavar, BAY43-9006), a bi-arylurea, is a newly established anti-cancer drug and its functional attribute of cytotoxicity is based on the multi-kinase inhibitory action. here, we report yet another novel pathway in which sorafenib can induce apoptotic cell death preferentially and efficaciously on an experimentally proven drug- and radio-resistant human hep G2 cells via a mitochondria-dependent oxidative stress mechanism. a real-time confocal imaging assay revealed that sorafenib could rapidly provoke the production of ROS plethorically, mainly concentrating in the mitochondria, albeit substantial amounts of ROS could also be detected in cytosol and nucleus. The rapid production of ROS could simultaneously induce intracellular glutathione (iGSH) depletion. a nearly 90% of iGSH was found to be depleted in 1h period after the cells received the drug treatment. Besides mitochondria, iGSH depletion could also be detected in other cellular compartment including cytoplasm and nucleus. Interestingly, we also demonstrated that sorafenib could trigger mitochondrial Ca2+ overload. all these events compoundedly serve as the final arbitrator to initiate lethal apoptotic process through the release of cytochrome c and caspase 3/7 activation. Collectively, we provide first evidence here that sorafenib can provoke an alternative pathway for apoptosis induction of Hep G2 cells through a mitochondria-dependent oxidative stress mechanism which is independent of original kinase inhibitory attribute of the drug action. Most importantly, we also demonstrate that sorafenib can effectively eradicate a highly drug- and radio-resistant HCC cells. Thus, our data can provide the basis for a potential applicability of sorafenib in a combined treatment modality.

AB - Sorafenib (Nexavar, BAY43-9006), a bi-arylurea, is a newly established anti-cancer drug and its functional attribute of cytotoxicity is based on the multi-kinase inhibitory action. here, we report yet another novel pathway in which sorafenib can induce apoptotic cell death preferentially and efficaciously on an experimentally proven drug- and radio-resistant human hep G2 cells via a mitochondria-dependent oxidative stress mechanism. a real-time confocal imaging assay revealed that sorafenib could rapidly provoke the production of ROS plethorically, mainly concentrating in the mitochondria, albeit substantial amounts of ROS could also be detected in cytosol and nucleus. The rapid production of ROS could simultaneously induce intracellular glutathione (iGSH) depletion. a nearly 90% of iGSH was found to be depleted in 1h period after the cells received the drug treatment. Besides mitochondria, iGSH depletion could also be detected in other cellular compartment including cytoplasm and nucleus. Interestingly, we also demonstrated that sorafenib could trigger mitochondrial Ca2+ overload. all these events compoundedly serve as the final arbitrator to initiate lethal apoptotic process through the release of cytochrome c and caspase 3/7 activation. Collectively, we provide first evidence here that sorafenib can provoke an alternative pathway for apoptosis induction of Hep G2 cells through a mitochondria-dependent oxidative stress mechanism which is independent of original kinase inhibitory attribute of the drug action. Most importantly, we also demonstrate that sorafenib can effectively eradicate a highly drug- and radio-resistant HCC cells. Thus, our data can provide the basis for a potential applicability of sorafenib in a combined treatment modality.

KW - Anti-cancer drug

KW - Apoptosis

KW - Confocal

KW - Hepatocellular carcinoma cell

KW - Mitochondria

KW - Oxidative stress mechanism

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=73549094006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73549094006&partnerID=8YFLogxK

U2 - 10.4161/cbt.8.20.9436

DO - 10.4161/cbt.8.20.9436

M3 - Article

C2 - 19770576

AN - SCOPUS:73549094006

VL - 8

SP - 1904

EP - 1913

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 20

ER -